SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: marc ultra who wrote (2214)8/20/1998 11:16:00 PM
From: growthvalue  Read Replies (1) | Respond to of 4676
 
The risk of fomivirsen not being approved by the FDA is smaller than was the risk of the advisory panel not recommending it (which was small in the first place). I still don't think it'll be a big deal.

Although one never knows....

GV



To: marc ultra who wrote (2214)8/25/1998 12:05:00 PM
From: Edward Paule  Read Replies (1) | Respond to of 4676
 
Remember, the 5-2 vote wasn't 5 for approval and 2 against approval. The vote was 7 for approval and 0 against approval. The 2 negative votes were against the first-line-of-defense labelling. They felt the drug should be approved but only as a last-line-of-defense.

Also, I just bought more shares at these bargain basement prices.

- Ed.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News